242 related articles for article (PubMed ID: 37361539)
21. Enteric neural crest differentiation in ganglioneuromas implicates Hedgehog signaling in peripheral neuroblastic tumor pathogenesis.
Gershon TR; Shiraz A; Qin LX; Gerald WL; Kenney AM; Cheung NK
PLoS One; 2009 Oct; 4(10):e7491. PubMed ID: 19834598
[TBL] [Abstract][Full Text] [Related]
22. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
Yang XH; Tang F; Shin J; Cunningham JM
BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
[TBL] [Abstract][Full Text] [Related]
23. Expression of the apoptosis-suppressing gene BCL-2 in pheochromocytoma is associated with the expression of C-MYC.
Wang DG; Johnston CF; Marley JJ; Phenix KV; Atkinson AB; Russell CF; Buchanan KD
J Clin Endocrinol Metab; 1997 Jun; 82(6):1949-52. PubMed ID: 9177412
[TBL] [Abstract][Full Text] [Related]
24. The MYCN oncogene and differentiation in neuroblastoma.
Westermark UK; Wilhelm M; Frenzel A; Henriksson MA
Semin Cancer Biol; 2011 Oct; 21(4):256-66. PubMed ID: 21849159
[TBL] [Abstract][Full Text] [Related]
25. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
[TBL] [Abstract][Full Text] [Related]
26. MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent.
Wang T; Liu L; Chen X; Shen Y; Lian G; Shah N; Davidoff AM; Yang J; Wang R
Cell Death Dis; 2018 Feb; 9(2):220. PubMed ID: 29445162
[TBL] [Abstract][Full Text] [Related]
27. WNT signaling, the development of the sympathoadrenal-paraganglionic system and neuroblastoma.
Becker J; Wilting J
Cell Mol Life Sci; 2018 Mar; 75(6):1057-1070. PubMed ID: 29058015
[TBL] [Abstract][Full Text] [Related]
28. Neuroblastoma models for insights into tumorigenesis and new therapies.
Kiyonari S; Kadomatsu K
Expert Opin Drug Discov; 2015 Jan; 10(1):53-62. PubMed ID: 25345447
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical analysis of N-myc protein expression in neuroblastoma: correlation with prognosis of patients.
Hiyama E; Hiyama K; Yokoyama T; Ishii T
J Pediatr Surg; 1991 Jul; 26(7):838-43. PubMed ID: 1895195
[TBL] [Abstract][Full Text] [Related]
30. Neuroblastoma: When differentiation goes awry.
Zeineldin M; Patel AG; Dyer MA
Neuron; 2022 Sep; 110(18):2916-2928. PubMed ID: 35985323
[TBL] [Abstract][Full Text] [Related]
31. N-Myc overexpression leads to decreased beta1 integrin expression and increased apoptosis in human neuroblastoma cells.
van Golen CM; Soules ME; Grauman AR; Feldman EL
Oncogene; 2003 May; 22(17):2664-73. PubMed ID: 12730680
[TBL] [Abstract][Full Text] [Related]
32. MYCN induces neuroblastoma in primary neural crest cells.
Olsen RR; Otero JH; García-López J; Wallace K; Finkelstein D; Rehg JE; Yin Z; Wang YD; Freeman KW
Oncogene; 2017 Aug; 36(35):5075-5082. PubMed ID: 28459463
[TBL] [Abstract][Full Text] [Related]
33. Renin in cultured cells of neural crest origin (abstract).
Okamura T; Toda N; Inagami T
Jpn Circ J; 1984 Nov; 48(11):1225-7. PubMed ID: 6389919
[No Abstract] [Full Text] [Related]
34. Constitutively active TrkB confers an aggressive transformed phenotype to a neural crest-derived cell line.
Dewitt J; Ochoa V; Urschitz J; Elston M; Moisyadi S; Nishi R
Oncogene; 2014 Feb; 33(8):977-85. PubMed ID: 23455321
[TBL] [Abstract][Full Text] [Related]
35. Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells.
Montavon G; Jauquier N; Coulon A; Peuchmaur M; Flahaut M; Bourloud KB; Yan P; Delattre O; Sommer L; Joseph JM; Janoueix-Lerosey I; Gross N; Mühlethaler-Mottet A
Oncotarget; 2014 Jun; 5(12):4452-66. PubMed ID: 24947326
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia-inducible Factor 2α: A Key Player in Tumorigenesis and Metastasis of Pheochromocytoma and Paraganglioma?
Bechmann N; Eisenhofer G
Exp Clin Endocrinol Diabetes; 2022 May; 130(5):282-289. PubMed ID: 34320663
[TBL] [Abstract][Full Text] [Related]
37. Role of hypoxia and HIF2α in development of the sympathoadrenal cell lineage and chromaffin cell tumors with distinct catecholamine phenotypic features.
Richter S; Qin N; Pacak K; Eisenhofer G
Adv Pharmacol; 2013; 68():285-317. PubMed ID: 24054150
[TBL] [Abstract][Full Text] [Related]
38. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
Rounbehler RJ; Li W; Hall MA; Yang C; Fallahi M; Cleveland JL
Cancer Res; 2009 Jan; 69(2):547-53. PubMed ID: 19147568
[TBL] [Abstract][Full Text] [Related]
39. Childhood tumors of the nervous system as disorders of normal development.
Grimmer MR; Weiss WA
Curr Opin Pediatr; 2006 Dec; 18(6):634-8. PubMed ID: 17099362
[TBL] [Abstract][Full Text] [Related]
40. MYCN downregulates integrin alpha1 to promote invasion of human neuroblastoma cells.
Tanaka N; Fukuzawa M
Int J Oncol; 2008 Oct; 33(4):815-21. PubMed ID: 18813796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
